DexCom (DXCM) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
DexCom, Inc. (DXCM) insider buying and selling: 1 purchase, 31 sales
84 Form 4 Table I transactions filed with the SEC by DexCom, Inc. insiders between 2025-09-04 and 2026-10-19 (15-month history): 1 open-market purchase and 31 sales, plus 52 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $2.4M by Sayer Kevin R on 2026-08-20.
DexCom insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, DexCom insiders filed 1 purchase worth $1.0M and 28 sales worth $12.8M on the open market. The net balance is on the sell side: $11.8M more sold than bought.
The biggest buyer was Leach Jacob Steven (President & COO): $1.0M in 1 purchase, the only buyer. The biggest seller was Sayer Kevin R (Executive Chair): $8.3M in 4 sales, out of 9 different sellers.
The largest trade of the period was a sale of $2.4M on Aug 20, 2026, by Sayer Kevin R (Executive Chair), under a 10b5-1 plan. Form 4 on sec.gov (0001093557-26-000151).
All 28 sales carry the 10b5-1 plan flag on the Form 4: scheduled months ahead.
The last three months show 0 purchases and 12 sales, against 0 and 10 in the three before. The latest purchase is from Nov 10, 2025; the latest sale from Oct 15, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. DexCom has more sales than 50 of the other 58, ranks 35 of 59 by net dollars sold, and 19 of the 59 have at least one purchase, DexCom included.
The 20 most important trades
The only open-market purchase first, then the rest, each type from largest to smallest. The full history is in the tool above, already searched.
See all 84 DXCM trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2025-11-10 | 2025-11-10 | Leach Jacob Steven | President & COO | $1.0M | P — Open-market purchase3 Form 4 footnotesF1 This transaction was executed in multiple trades at prices ranging from $54.34 to $55.33. The price above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 This transaction was executed in multiple trades at prices ranging from $55.34 to $55.55. The price above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 Included in this number are 84,537 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 8,465 of which were granted on March 8, 2023 and shall vest through March 8, 2026. | SEC |
| 2026-08-20 | 2026-08-24 | Sayer Kevin R | Executive Chair | $2.4M | S — Open-market sale (scheduled 10b5-1)4 Form 4 footnotesF1 On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2 This transaction was executed in multiple trades at prices ranging from $89.275 to $90.25. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. F4 This transaction was executed in multiple trades at prices ranging from $90.32 to $91.19. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. | SEC |
| 2026-07-20 | 2026-07-21 | Sayer Kevin R | Executive Chair | $2.0M | S — Open-market sale (scheduled 10b5-1)3 Form 4 footnotesF1 On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2 This transaction was executed in multiple trades at prices ranging from $75.80 to $76.62. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. | SEC |
| 2026-05-21 | 2026-05-26 | Sayer Kevin R | Executive Chair | $1.9M | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2 Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. | SEC |
| 2026-07-06 | 2026-07-07 | Sayer Kevin R | Executive Chair | $1.9M | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2 Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. | SEC |
| 2026-09-15 | 2026-09-16 | Augustinos Nicholas | Director | $550k | S — Open-market sale (scheduled 10b5-1) Indirect holding, through: by Trust 2 Form 4 footnotesF1 On June 10, 2026, Mr. Augustinos adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Augustinos. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 Shares are held by the Kirschner/Augustinos Revocable Trust, with respect to which the Reporting Person is a trustee. | SEC |
| 2026-06-04 | 2026-06-05 | Coleman Jon | EVP, Chief Commercial Officer | $364k | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 On March 4, 2026, Mr. Coleman adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Coleman. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2 Included in this number are 95,450 unvested restricted stock units, 43,897 of which were granted on March 8, 2026 and shall vest through March 8, 2029, and 51,553 of which were granted on May 22, 2025 and shall vest through May 22, 2029. | SEC |
| 2026-06-03 | 2026-06-05 | Coleman Jon | EVP, Chief Commercial Officer | $359k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 On March 4, 2026, Mr. Coleman adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Coleman. The shares set forth above were sold pursuant to the 10b5- 1 Plan. | SEC |
| 2025-09-02 | 2025-09-04 | Sylvain Jereme M | EVP, Chief Financal Officer | $358k | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 On May 27, 2025, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 Included in this number are 83,328 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026. | SEC |
| 2026-09-10 | 2026-09-14 | Sylvain Jereme M | EVP, Chief Financal Officer | $303k | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 On June 10, 2026, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 Included in this number are 87,094 unvested restricted stock units, 48,774 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 76 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan. | SEC |
| 2026-06-15 | 2026-06-17 | Foletta Mark G | Director | $297k | S — Open-market sale (scheduled 10b5-1) Indirect holding, through: by Trust 4 Form 4 footnotesF1 On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 This transaction was executed in multiple trades at prices ranging from $73.70 to $74.685. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee. F4 This transaction was executed in multiple trades at prices ranging from $74.78 to $75.55. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. | SEC |
| 2026-08-27 | 2026-08-28 | Stern Sadie | EVP Chief People & Culture Off | $227k | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 On May 28, 2026, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 Included in this number are 71,903 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027. | SEC |
| 2026-09-28 | 2026-09-30 | Stern Sadie | EVP Chief People & Culture Off | $221k | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 On May 28, 2026, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 Included in this number are 71,903 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027. | SEC |
| 2025-11-10 | 2025-11-10 | Collins Richard Alexander | Director | $218k | S — Open-market sale (scheduled 10b5-1) Indirect holding, through: by Trust 2 Form 4 footnotesF1 On August 7, 2025, the Richard A. Collins Revocable Trust (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 Shares are held by the Richard A. Collins Revocable Trust, with respect to which the reporting person is a trustee. | SEC |
| 2025-11-14 | 2025-11-17 | Collins Richard Alexander | Director | $172k | S — Open-market sale (scheduled 10b5-1) Indirect holding, through: by Trust 2 Form 4 footnotesF1 On August 7, 2025, the Richard A. Collins Revocable Trust (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 Shares are held by the Richard A. Collins Revocable Trust, with respect to which the reporting person is a trustee. | SEC |
| 2026-08-03 | 2026-08-04 | Foletta Mark G | Director | $171k | S — Open-market sale (scheduled 10b5-1) Indirect holding, through: by Trust 2 Form 4 footnotesF1 On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee. | SEC |
| 2026-07-31 | 2026-08-04 | Foletta Mark G | Director | $160k | S — Open-market sale (scheduled 10b5-1) Indirect holding, through: by Trust 2 Form 4 footnotesF1 On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee. | SEC |
| 2026-08-14 | 2026-08-17 | Brown Michael Jon | EVP Chief Legal Compliance Off | $156k | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 On November 26, 2025, Mr. Brown adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Brown. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2 Included in this number are 74,753 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 8,549 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027. | SEC |
| 2026-10-15 | 2026-10-19 | Brown Michael Jon | EVP Chief Legal Compliance Off | $145k | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 On November 26, 2025, Mr. Brown adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Brown. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2 Included in this number are 71,903 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027. | SEC |
| 2026-09-15 | 2026-09-16 | Brown Michael Jon | EVP Chief Legal Compliance Off | $143k | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 On November 26, 2025, Mr. Brown adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Brown. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2 Included in this number are 71,903 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 83 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan. | SEC |
The period balance: money in, money out
Across the Form 4 filings submitted between Sep 4, 2025 and Oct 19, 2026, DexCom, Inc. open-market activity adds up to 1 purchase worth $1.0M and 31 sales worth $13.3M. The net balance is $12.3M on the sell side.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like DexCom, Inc.'s is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| S | Open-market sale | 31 | $13.3M |
| A | Grant or award | 24 | $0 |
| F | Tax withholding (shares surrendered for taxes) | 19 | $12.4M |
| G | Gift | 9 | $0 |
| P | Open-market purchase | 1 | $1.0M |
| Total | Everything filed in the period | 84 | $26.7M |
33 of the 84 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 17 distinct people or entities have filed DexCom, Inc. transactions: 1 bought on the open market and 10 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
Of the 10 who sold on the open market (31 sales in all), the three biggest sellers account for $10.0M of the $13.3M: 76% of the money in three people.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Sayer Kevin R | Executive Chair | 8 | — | $8.3M (4) | 2026-08-24 |
| Brown Michael Jon | EVP Chief Legal Compliance Off | 14 | — | $1.0M (8) | 2026-10-19 |
| Leach Jacob Steven | President, CEO, and Director | 7 | $1.0M (1) | — | 2026-08-25 |
| Coleman Jon | EVP, Chief Commercial Officer | 4 | — | $723k (2) | 2026-06-05 |
| Augustinos Nicholas | Director | 6 | — | $680k (2) | 2026-09-16 |
| Sylvain Jereme M | EVP, Chief Financal Officer | 8 | — | $661k (2) | 2026-09-14 |
| Foletta Mark G | Director | 6 | — | $627k (3) | 2026-08-04 |
| Stern Sadie | EVP Chief People & Culture Off | 9 | — | $565k (3) | 2026-09-30 |
Shown here are the 8 who moved the most money, out of 17. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Aug 2026: 0 purchases and 5 sales, worth $3.1M. 4 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 0 | $0 |
| Sep 2025 | 0 | $0 | 3 | $529k |
| Oct 2025 | 0 | $0 | 0 | $0 |
| Nov 2025 | 1 | $1.0M | 3 | $448k |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 1 | $69k |
| Mar 2026 | 0 | $0 | 1 | $110k |
| Apr 2026 | 0 | $0 | 1 | $107k |
| May 2026 | 0 | $0 | 3 | $2.1M |
| Jun 2026 | 0 | $0 | 4 | $1.1M |
| Jul 2026 | 0 | $0 | 4 | $4.3M |
| Aug 2026 | 0 | $0 | 5 | $3.1M |
| Sep 2026 | 0 | $0 | 5 | $1.3M |
| Oct 2026 | 0 | $0 | 1 | $145k |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
DexCom, Inc. (DXCM) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
19 of the 19 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. DexCom's single open-market purchase (code P) is the rare signal: insiders are already paid in stock, so buying more means putting in their own money. The latest filing is from Oct 19, 2026, and a Form 4 arrives up to two business days after the trade.
20 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.